)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Wave Life Sciences (WVE) investor relations material
Wave Life Sciences Study Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study Update summary8 Dec, 2025
Study Design and Objectives
INLIGHT is a randomized, double-blind, placebo-controlled Phase 1 trial in overweight or mildly obese adults (BMI ~32), with no diet or exercise modifications required and over 100 enrolled across US and Europe.
Dosing cohorts included single ascending doses of 75 mg, 240 mg, 400 mg, and 600 mg, with 32 subjects per therapeutic cohort and body composition measured by DEXA.
The study assesses safety, tolerability, pharmacokinetics, and pharmacodynamics, with exploratory endpoints including body composition, biomarkers, and body weight.
Baseline characteristics were balanced across arms, with mean BMI around 32 kg/m².
No diet or exercise modifications were instituted during the trial.
Key Interim Results
A single 240 mg dose of WVE-007 led to a 9.4% reduction in visceral fat, 4.5% reduction in total fat mass, and a 3.2% increase in lean mass at three months, with no significant changes in the placebo group.
Placebo-adjusted reductions in total fat mass and visceral fat were on par or greater than those seen with semaglutide at 12 weeks, but with preservation of lean mass.
Durable, dose-dependent reductions in serum Activin E (>75%) were achieved, supporting the potential for once or twice-yearly dosing.
All adverse events were mild, with no discontinuations, serious events, deaths, or clinically meaningful lab changes through 600 mg.
No clinically meaningful changes in lipids or other laboratory measurements, including liver function tests, were observed.
Mechanism and Differentiation
WVE-007 is a GalNAc-siRNA targeting INHBE (Inhibin E), reducing hepatic Activin E production and promoting adipocyte lipolysis, leading to fat loss while preserving muscle.
The approach is orthogonal to GLP-1s, which act via appetite suppression and often cause muscle loss.
Human genetic data support the mechanism, with INHBE loss-of-function carriers showing healthier metabolic profiles.
Proprietary SpiNA chemistry enhances silencing potency and durability, differentiating WVE-007 from other siRNA approaches.
Preclinical data in mice showed durable reductions in Activin E, significant fat loss, and muscle preservation after a single dose.
How does WVE-007 align with FDA's fat loss focus?
Prioritize Phase II settings for WVE-007
Expected fat loss kinetics beyond 3 months?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Wave Life Sciences earnings date
Q4 20254 Mar, 2026
Next Wave Life Sciences earnings date
Q4 20254 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Wave Life Sciences Ltd. (WVE) is a biotechnology company leveraging its proprietary RNA medicines platform, PRISM, to develop transformative treatments for a range of genetic diseases. This platform enables the design, optimization, and production of novel stereopure oligonucleotides, aimed at correcting disease-causing mutations, modulating protein activity, and restoring functional protein production or reducing disease-promoting RNAs or proteins. Wave's diverse pipeline includes clinical programs targeting Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, Huntington's disease, and a preclinical program for obesity, among others. Their approach includes multiple RNA-targeting modalities such as editing, splicing, RNA interference, and antisense silencing, showcasing their broad capabilities in addressing complex disease biology. The company is headquartered in Singapore, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage